Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lyra Therapeutics Inc LYRA

Healthcare Biotechnology
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LYRA)

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 12, 2024

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

GlobeNewswire October 15, 2024

Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings

GlobeNewswire September 27, 2024

Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 14, 2024

Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

GlobeNewswire May 21, 2024

Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

GlobeNewswire May 6, 2024

Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire April 30, 2024

Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 26, 2024

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 21, 2024
View More News ››

Opinion & Analysis (NDAQ:LYRA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LYRA)

Lyra Therapeutics to Present Study Results for LYR-210 and L

BREAKING NEWS: $LYRA Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS...
whytestocks - September 27, 2024

Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views | Benz

JUST IN: $LYRA Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views | BenzingaU.S. stocks traded higher this morning, with the Nasdaq...
whytestocks - May 6, 2024
View more Bullboard ››

Innocan Pharma Corp

Innocan Pharma Corp

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the ...
View More »